objective identical doubleblind trials tobramycin solution inhalation tobi pathogenesis corporation seattle washington cystic fibrosis patients chronic pseudomonas aeruginosa infection conducted united states aim present study extrapolate trial data canadian setting using canadian costs estimate savings direct medical costs result use similar tobi regimen versus usual care NUMBER canadian provinces background cystic fibrosis genetic disease persistent respiratory infection usually p aeruginosa infection major cause morbidity mortality methods trials demonstrated tobi produced significant improvements pulmonary function test results reduced sputum levels p aeruginosa resulted NUMBER reduction probability hospitalization NUMBER ci vs placebo clinical trials individual patient data trials used calculate mean number days hospital mean number days home intravenous oral antibiotic therapy adjust canadian pricing pertinent economic data obtained statistics canada ontario quebec health ministries demographic baseline data obtained health surveys conducted canadian cystic fibrosis foundation results economic analysis showed use tobi NUMBER weeks result estimated mean savings direct medical costs canadian dollars NUMBER ontario NUMBER quebec substantially offset canadian acquisition price NUMBER period conclusions assuming percentage reduction hospital days observed trials occur canadian clinical setting use tobi reduce use health care services particularly hospital days lead substantial savings direct medical costs offset acquisition price reduction actually occurs tobi enters canadian market subject future investigation NUMBER week placebo controlled NUMBER week NUMBER NUMBER patient NUMBER week